Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Ltd | Sector: Pharmaceuticals | ISIN: INE268B01013

₹ 70.40 (-1.54%) icon7 May, 2024, 12:00:00 AM

undefined KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 5/7/2024 12:00:00 AM

    ₹ 70.4 -1.10 -1.54
  • Open
  • ₹ 71.75
  • Prev. Close
  • ₹ 71.5
  • Turnover(Lac.)
  • ₹ 4
  • Day's High
  • ₹ 73
  • Day's Low
  • ₹ 68.3
  • 52 Week's High
  • ₹ 93.95
  • 52 Week's Low
  • ₹ 59.2
  • Book Value
  • ₹ -52.57
  • Face Value
  • ₹ 10
  • Mkt Cap (₹ Cr.)
  • 151.79
  • P/E
  • 0
  • EPS
  • 0
  • Divi. Yield
  • 0

undefined Corporate Actions

No Record Found


Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

undefined SHAREHOLDING SNAPSHOT
08 May , 2024 | 07:51 AM

PROMOTER - TOTAL72.74%

Indian: 72.74%

Foreign: 0%

NON-PROMOTER - TOTAL 27.26%

Institutions: 0.50%

Non-Institutions: 26.76%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

undefined FINANCIALS

View Profit & Loss Graph

undefined PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT undefined

  • G V L Prasad
  • Independent Director
  • R T Ravi
  • Chairman (Non-Executive)
  • Avinash Ravi
  • Non Executive Director
  • Tangirala Malati
  • Independent Director
  • Satish Khivsara
  • Independent Director
  • Raj Kamal Prasad Verma
  • Independent Director
  • Rohit Taparia
  • Company Sec. & Compli. Officer
  • Jitendra Shah
  • Managing Director

Summary

Krebs Biochemicals & Industries Ltd (Formerly Krebs Biochemicals Ltd), promoted by R T Ravi in 1991 is engaged in the manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same.Krebs develops commercially viable biotech processes for application in medicine, agriculture and industry. Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies.KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA. KBL went to public with an IPO in 1994. During 2001-02, the company launched Vitamin C(I P Grade) through Fermentation Process. The Company commissioned 2.5 MW Co-generation Power Plant at Unit II in Vizag during 2003-04 and started operations on it from July, 2004... Read More


Reports by


Reports by

Company FAQ

No Record Found